




BMJ Open Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial

Joanna SJ Vinke ¹, Michele F Eisenga ¹, Jan-Stephan F Sanders,¹ Stefan P Berger,¹ Jacoba M Spikman,² Wayel H Abdulahad,³ Stephan JL Bakker,¹ Carlo A J M Gaillard,⁴ Arjan D van Zuilen,⁴ P van der Meer,⁵ Martin H de Borst ¹

To cite: Vinke JSJ, Eisenga MF, Sanders J-SF, *et al.* Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial. *BMJ Open* 2023;**13**:e065423. doi:10.1136/bmjopen-2022-065423

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-065423>).

Received 04 June 2022
Accepted 07 March 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Prof Martin H de Borst;
m.h.de.borst@umcg.nl

ABSTRACT

Introduction Iron deficiency (ID) is common and has been associated with an excess mortality risk in kidney transplant recipients (KTRs). In patients with chronic heart failure and ID, intravenous iron improves exercise capacity and quality of life. Whether these beneficial effects also occur in KTRs is unknown. The main objective of this trial is to address whether intravenous iron improves exercise tolerance in iron-deficient KTRs.

Methods and analysis The Effect of Ferric Carboxymaltose on Exercise Capacity after Kidney Transplantation study is a multicentre, double-blind, randomised, placebo-controlled clinical trial that will include 158 iron-deficient KTRs. ID is defined as plasma ferritin <100 µg/L or plasma ferritin 100–299 µg/L with transferrin saturation <20%. Patients are randomised to receive 10 mL of ferric carboxymaltose (50 mg Fe³⁺/mL, intravenously) or placebo (0.9% sodium chloride solution) every 6 weeks, four dosages in total. The primary endpoint is change in exercise capacity, as quantified by the 6 min walk test, between the first study visit and the end of follow-up, 24 weeks later. Secondary endpoints include changes in haemoglobin levels and iron status, quality of life, systolic and diastolic heart function, skeletal muscle strength, bone and mineral parameters, neurocognitive function and safety endpoints. Tertiary (explorative) outcomes are changes in gut microbiota and lymphocyte proliferation and function.

Ethics and dissemination The protocol of this study has been approved by the medical ethical committee of the University Medical Centre Groningen (METc 2018/482;) and is being conducted in accordance with the principles of the Declaration of Helsinki, the Standard Protocol Items: Recommendations for Interventional Trials checklist and the Good Clinical Practice guidelines provided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Study results will be disseminated through publications in peer-reviewed journals and conference presentations.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This double-blind, randomised, placebo-controlled trial will be the first intervention study to provide information on the effect of intravenous iron supplementation on exercise capacity in kidney transplant recipients with iron deficiency.
- ⇒ Several clinically relevant additional endpoints are assessed, including changes in quality of life, cardiac function, skeletal muscle strength, neurocognitive function and safety endpoints including effects of phosphate homeostasis.
- ⇒ A limitation of this study is that it is insufficiently powered to detect differences on clinical endpoints such as cardiovascular events or mortality.

Trial registration number NCT03769441.

INTRODUCTION

After kidney transplantation, exercise capacity and skeletal muscle strength improve compared with the dialysis setting, but this improvement is often incomplete.^{1 2} Reduced physical activity and muscle strength have been associated with an excess risk of mortality and worse graft outcomes in kidney transplant recipients (KTRs).^{3 4} Although patient and graft survival have substantially improved over the past decades, few therapeutic strategies are available to ameliorate physical fitness and well-being. Therefore, it is key to identify new modifiable risk factors related to impaired exercise tolerance.

Iron deficiency (ID) is common after kidney transplantation, with reported prevalences ranging between 11% and 47%, depending on the definition and time

after transplantation.^{5–9} ID has been associated with an increased risk of mortality in KTRs, independent of coexisting anaemia.⁵ Iron is involved in oxygen transport as a component of haemoglobin. Moreover, ID has implications beyond impaired erythropoiesis as iron is crucial to myriad physiological processes. Iron is a cofactor of many enzymes involved in different cellular functions: as a constituent of aconitase and succinate dehydrogenase, both enzymes involved in the Krebs cycle, and as a constituent of different complexes involved in the mitochondrial respiratory chain, iron is pivotal to cellular energy metabolism. Additionally, iron is involved in nucleotide synthesis for replication and production of DNA and RNA.¹⁰ Therefore, ID may affect growth and function of many cell types, in particular those with high energy consumption or mitogenic activity.

Skeletal muscle cells and cardiomyocytes are among the cells with the highest energy demand, and ID compromises their aerobic metabolism and function.^{11–16} In patients with chronic heart failure (CHF), ID is associated with impaired exercise tolerance, skeletal muscle strength and quality of life, and worse prognosis.^{17–23} Intravenous correction of ID improves exercise capacity, quality of life,^{24–27} left^{28 29} and right^{29 30} ventricular function and skeletal muscle energy metabolism³¹ in CHF patients and reduces the incidence of heart failure hospitalisations.³² In chronic obstructive pulmonary disease patients, intravenous correction of ID also improves exercise capacity and quality of life.³³ In patients with chronic kidney disease (CKD), ID has been associated with fatigue,³⁴ lower physical quality of life³⁵ and higher risk of cardiovascular events and premature mortality.^{36–40} In a relatively small trial in patients with non-anaemic CKD, there was a non-significant trend towards an improvement of exercise capacity and quality of life after intravenous iron supplementation.⁴¹ Furthermore, a high-dose intravenous iron regime in patients undergoing haemodialysis was associated with a better prognosis, compared with a low-dose regime in the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial.⁴² The impact of ID and its correction on muscle strength and physical function in KTRs is yet unknown. The Effect of Ferric Carboxymaltose on Exercise Capacity after Kidney Transplantation (EFFECT-KTx) trial has been designed to test the hypothesis that iron supplementation improves exercise capacity, skeletal muscle strength, cardiac function and quality of life in iron-deficient KTRs.

Additionally, the study provides an opportunity to assess the effect of iron supplementation on several other organ systems and physical functions. First, correction of ID might improve neurocognitive functions such as memory, mental speed and executive functioning, which are compromised after kidney transplantation.^{43 44} In addition to its role in energy metabolism, iron is involved in neurotransmitter synthesis and uptake and neuron myelination.⁴⁵ ID is associated with impaired cognitive function,^{46–51} which can be improved by iron supplementation.^{47 52 53} Second, ID correction after kidney

transplantation might ameliorate lymphocyte proliferation and function. Lymphocytes are among the cells with the highest mitogenic activity, and therefore it would be relevant to address whether ID correction changes lymphocyte proliferation and function, and potentially rates of infection and rejection, after kidney transplantation.^{54 55} While it is unknown whether iron supplementation improves resistance against pathogens in KTRs, prior studies dispute whether iron sufficiency and iron supplementation might increase rejection risk.^{56 57} Third, ID correction might alter the synthesis of fibroblast growth factor (FGF) 23, which is deregulated during ID.^{58 59} FGF23, a phosphaturic hormone secreted by osteocytes, is increased in CKD and often remains elevated after kidney transplantation.^{60 61} By promoting excessive phosphaturia and by lowering levels of 1,25-dihydroxycholecalciferol,⁶⁰ FGF23 might compromise bone mineral density^{62 63} and increase fracture risk.⁶⁴ In addition, FGF23 may induce left ventricular hypertrophy through off-target effects on cardiomyocytes,⁶⁵ and C-terminal FGF23 has been shown to (partially) mediate the association between ID and outcomes in KTRs and other populations.^{38 66–68} In KTRs, a higher plasma FGF23 level is associated with worse patient and graft survival.^{69 70} Interestingly, prior studies have shown that in the short-term, ferric carboxymaltose induces an increase of FGF23, potentially triggered by its carboxymaltose shell.^{58 71} While the long-term effect of ferric carboxymaltose on FGF23 levels in KTRs is currently unknown, this short-term upregulation might induce hypophosphatemia and may be a relevant potential safety signal that will be evaluated in the EFFECT-KTx trial.

As exploratory endpoints, the effects of intravenous iron supplementation on gut microbiome composition and the presence of gastrointestinal symptoms will be assessed. Oral iron supplements are known to change the gut microbiome in favour of pathogenic bacteria, which are iron dependent,⁷² and it has been suggested that intravenous iron supplementation also affects the gut microbiome⁷³ and metabolome.⁷⁴ Furthermore, since ID has been linked to restless legs syndrome^{75 76} and ID correction has been shown to alleviate restless legs symptoms,^{77–79} intravenous iron might reduce these complaints in KTRs.⁸⁰

The EFFECT-KTx trial addresses the effects of iron treatment using an intravenous solution. Apart from the potential adverse effects of oral iron supplements on the gut microbiome and its gastrointestinal side effects, which may impair quality of life as well as treatment adherence,⁸¹ intravenous iron supplementation may also have a better treatment effect in KTRs. In patients with CHF⁸² or CKD,⁸³ it has been shown that intravenous iron supplementation is a more effective way to correct iron parameters, compared with oral iron treatment. In a patient with CHF, several trials show a positive effect of intravenous iron supplementation on exercise capacity,^{25–27 84} but do not show the same effect of oral iron treatment.⁸⁵ Mechanistically, patients with CHF or CKD may suffer from




Figure 1 Design of the Effect of Ferric Carboxymaltose on Exercise Capacity after Kidney Transplantation study. 6MWT, 6 min walk test; FCM, ferric carboxymaltose; TSAT, transferrin saturation.

chronic inflammation, leading to higher hepcidin levels, which hypothetically could hamper the intestinal absorption of iron. This may also apply to KTRs.

Together, the EFFECT-KTx trial will provide important information on health effects of ID correction by intravenous ferric carboxymaltose in KTRs, with a primary focus on exercise capacity.

METHODS AND ANALYSIS

Overall design

The EFFECT-KTx study is designed as an investigator-initiated, multicentre, randomised placebo-controlled clinical superiority trial with two parallel treatment arms. The study design is shown in figure 1. Study medication (ferric carboxymaltose or placebo, allocation ratio 1:1) is administered at a baseline visit and at subsequent study visits 6, 12 and 18 weeks later. Study participants are screened and recruited at the University Medical Centre Groningen (UMCG) and the University Medical Centre Utrecht, both in the Netherlands. KTRs with ID, defined as plasma ferritin <100 µg/L or plasma ferritin 100–299 µg/L with transferrin saturation (TSAT) <20%, and a haemoglobin level of ≥10.5 g/dL, who are at least 6 months after transplantation, may be eligible for participation. Inclusion and exclusion criteria are listed in box 1.

Patient and public involvement

During the feasibility stage, a concept version of the project plan was presented to the Dutch Kidney Patient Association (NVN) and was reviewed by an NVN employee and a kidney patient. Their advice to minimise the effort patients are required to make while participating in the trial was taken into consideration during the writing of the study design. They approved the choice of outcome parameters. In accordance with the NVN recommendation, an informative event will be organised and a study newsletter will be composed to inform the participants and other KTRs about the results of the study after they have been published.

Sample size calculation

Based on an average 6 min walking distance of 495±92 m, as previously reported in stable KTRs,¹ an anticipated improvement in walking distance of at least 10%,

a desired power of 0.90 with a significance level of 0.05, we calculated that a sample size of 72 participants per arm is needed to establish a clinically meaningful effect of intravenous iron on the primary endpoint, using a two-sided independent samples t-test. To account for possible dropout of up to 10% of enrolled participants, we aim to include 79 participants per arm (158 participants in total).

Randomisation

Participants are randomised by the UMCG hospital pharmacy using a precomposed list of usable participant numbers, which are assigned to a study arm. The

Box 1 Inclusion and exclusion criteria for the EFFECT-KTx trial

Inclusion criteria

- ⇒ Kidney transplant recipient
- ⇒ Iron deficiency at two consecutive measurements with an interval of at least a week, defined as plasma ferritin <100 µg/L or plasma ferritin 100–299 µg/L with transferrin saturation <20%
- ⇒ ≥6 months after kidney transplantation
- ⇒ ≥18 years of age
- ⇒ Ability to comply with the study protocol
- ⇒ Informed consent

Exclusion criteria

- ⇒ Known intolerance to intravenous iron products
- ⇒ Severe (Hb <10.5 g/dL) or progressive anaemia (Hb decline of ≥3.2 g/dL in 2 months) or a reduced mean corpuscular erythrocyte volume (<80 fL)
- ⇒ Recent history of gastrointestinal or urogenital blood loss or a positive faecal occult blood test
- ⇒ Erythrocyte transfusion ≤6 weeks prior to inclusion
- ⇒ Polycythaemia (Hb >15.3 g/dL) or a known history of haemochromatosis
- ⇒ Estimated glomerular filtration rate of ≤30 mL/min per 1.73 m²
- ⇒ Symptomatic coronary artery disease or myocardial infarction ≤4 weeks prior to inclusion
- ⇒ Disability to walk
- ⇒ Severe hypophosphatemia (plasma phosphate <0.35 mmol/L) ≤4 weeks prior to inclusion
- ⇒ For women at childbearing age: pregnancy or disagreement to take adequate contraceptive precautions
- ⇒ Signs of an active systemic infection
- ⇒ Participation in another intervention study

participant numbers on the list are grouped in blocks, with an equal distribution and a random order of treatment arm allocations within each block. To stratify for treatment centre, all study numbers within a certain block are assigned to participants in the same centre, in the order of the list. Other than to the pharmacist, the list is not accessible to any of the investigators or to others. In case of a medical emergency possibly related to the study treatment, treatment allocation may be revealed by the pharmacist.

Study drug and blinding

Patients in the active treatment arm receive ferric carboxymaltose (Ferinject, provided by Vifor Pharma, Glattbrugg, Switzerland), administered intravenously as 10 mL doses, each containing 500 mg of elemental iron, dissolved in 240 mL 0.9% sodium chloride. Patients in the placebo arm receive 250 mL 0.9% sodium chloride, administered intravenously as well. All treatments are followed by a 30 min observation period. Treatments are performed by an unblinded study nurse, who is not involved in any other study activities. Since ferric carboxymaltose is a dark brown liquid, participant blinding is maintained by using non-transparent infusion lines (Codan, Lensahn, Germany) or by opaque infusion line protection covers (Medipak, Winchester, Virginia, USA). Additionally, infusion lines and bags are covered with aluminium foil. All patients receive four doses of study medication, with 6 week intervals, at the baseline visit and after 6, 12 and 18 weeks. Only in case of a systemic infection or hypophosphatemia, defined as a phosphate level of ≤ 0.50 mmol/L, on the day of the scheduled treatment, a dose is skipped. In case of imminent iron overload, defined as a plasma ferritin level of ≥ 800 μ g/L or a plasma ferritin level of 500 to 799 μ g/L, combined with a TSAT of $\geq 45\%$ on the day of the scheduled treatment, patients in the intervention arm receive placebo instead of ferric carboxymaltose. This is decided by the unblinded study nurse according to a standard operating procedure that was designed for this purpose, without interference of the blinded study personnel. For optimal adherence, participants are encouraged to attend all study visits. To evaluate adherence to the protocol, drug accountability is performed by the pharmacy. In case the allocated treatment is not administered, the medication is returned to the pharmacy with an explanation from the study doctor or study nurse. Other healthcare providers such as the general practitioner and the nephrologist of the participant are discouraged to assess iron status and/or start oral iron treatment during trial participation, unless there is a strict medical indication.

Data collection and study endpoints

At the baseline visit, a full medical history is taken, including any current medication use. A physical examination, including assessment of weight, height and blood pressure, is performed as well. Blood pressure is measured three times, with at least 1 min between assessments,

using a Dinamap pressure metre. The mean of three measurements is calculated and recorded in the study file. Furthermore, iron intake is estimated using a food diary, which is completed by the participants on three representative days during the week before the baseline visit and after 24 weeks.

At all study visits, blood samples are taken for direct assessments (table 1) or storage. Furthermore, participants are asked to bring a 24-hour urine sample. Briefly, participants are instructed to discard their first morning urine on the day before the visit and collect urine throughout the following 24 hours, including the first morning urine of the day of the study visit. Participants are also asked to collect a faeces sample in a specific tube during the week before the baseline study visit and after 24 weeks, and to bring the frozen sample to the study centre, where it is stored for later analysis.

Once per year, a study monitor visits both study sites to inspect the accuracy of data collection and overall implementation of the study protocol. In addition, trial conduct will be audited at least once, independent from the investigators and sponsors. Since the safety risks of participation are considered low, no data monitoring board has been installed.

Primary endpoint

The primary endpoint of the study is change in exercise capacity, which is measured using the 6 min walk test (6MWT) at baseline and 24 weeks later.⁸⁶ The 6MWT, a validated measure of exercise capacity,⁸⁷ requires a quiet walking course with a flat, hard surface. Two traffic cones are placed at the beginning and at the end of a 15 m straight course and the participant is asked to walk around the two cones as fast as possible during 6 min, without running. If needed, participants may use a cane. During the test, the participant is encouraged verbally by the researcher. Before and immediately after the test, the heart rate is measured.

Secondary endpoints

Haematinic indices and iron parameters

Blood haemoglobin and haematocrit are measured at each study visit. Levels of plasma iron, ferritin and transferrin are assessed but are only available to the unblinded study nurse until after completion of the trial to avoid disclosure of treatment allocation to the blinded study team. TSAT is calculated as $100 \times \text{plasma iron } (\mu\text{mol/L}) \div (\text{plasma transferrin } (\text{g/L}) \times 25)$. Blood is stored for measurement of additional iron parameters, including hepcidin and soluble transferrin receptor.

Muscle mass and strength and functional mobility

At each study visit, 24-hour urinary creatinine excretion rate is measured to estimate muscle mass.⁸⁸ Skeletal muscle strength and functional mobility are assessed at the baseline visit and after 24 weeks using the Five Times Sit-to-Stand (FTSTS) Test, the Timed Up-and-Go (TUG) Test and a handgrip dynamometry. The FTSTS Test is

Table 1 Primary and secondary endpoints and exploratory outcomes

Primary endpoint	Measurements and tests	Study visits				
		Baseline	Week 6	Week 12	Week 18	Week 24
Exercise capacity	6 min walk test	x				x
Secondary endpoints						
Haematinic indices and iron status	Plasma haemoglobin	x	x	x	X	x
	Plasma iron, ferritin, transferrin saturation	x	x*	x*	x*	x*
	Soluble transferrin receptor	x		x		x
Muscle mass and strength and functional mobility	24-hour urinary creatinine excretion rate	x	x	x	x	x
	Five Times Sit-to-Stand Test	xx				x
	Timed Up-and-Go Test	x				x
	Handgrip dynamometry					x
Cardiac structure, function and strain	Resting transthoracic echocardiography	x				x
	Troponin-T	x		x		x
	N-terminal pro-B-type natriuretic peptide	x		x		x
Quality of life	Short Form-36	x				x
	Dutch 'Checklist Individuele Spankrant'	x				x
	Dutch Multifactor Fatigue Scale	x				x
	EuroQol-5D-5L	x				x
Bone and mineral metabolism	Plasma phosphate and 24-hour urinary phosphate excretion rate	x	x	x	x	x
	Plasma calcium and 24-hour urinary calcium excretion rate	x	x	x	x	x
	Parathyroid hormone	x	x	x	x	x
	C-terminal and total fibroblast growth factor 23	x	x	x	x	x
	25-hydroxycholecalciferol	x		x		x
	1,25-dihydroxycholecalciferol	x		x		x
Cognitive function	Cognitive Screening Test	x				
	Clock Drawing Test	x				
	Nederlandse Leestest voor Volwassenen	x				
	Digit Span Forward	x				x
	15 Words Test	x				x
	Word Fluency	x				x
	Symbol Digit Modalities Test	x				x
	Trail Making Test part A	x				x
	Trail Making Test part B	x				x
	Controlled Oral Word Association Test	x				x
	Digit Span Backward	x				x
Adverse effects and safety	Gastrointestinal Symptom Rating Scale	x	x	x	x	x
	Incidence of adverse symptoms and new clinical events	x	x	x	x	x
	Plasma creatinine					x
	Plasma aspartate transaminase	x	x	x	x	x
	Plasma alanine transaminase	x	x	x	x	x
Exploratory outcomes						
Incidence of restless leg syndrome (RLS)	Report of RLS-related symptoms	x	x	x	x	x
Kidney graft rejection and injury	Urine markers (kidney injury marker 1, neutrophil gelatinase-associated lipocalin)	x	x	x	x	x

Continued

Table 1 Continued

Primary endpoint	Measurements and tests	Study visits				
		Baseline	Week 6	Week 12	Week 18	Week 24
Function of the immune system	Analysis of peripheral blood mononuclear cells (growth, differentiation, immunoglobulin production, cytokine production)	x				x
	IgA, IgG, IgM	x				x
	Complement	x	x	x	x	x
	Cytokine levels	x				x
Gut microbiota	DNA sequencing of faecal samples	x				x

*Concealed to blinded study personnel.

used to measure leg strength by using the participant's body weight as resistance. Participants are asked to stand up from a chair five times successively as fast as possible, without support of their arms. The time required to do this is recorded. The task is repeated three times, and the mean of the attempts is calculated. The TUG Test is an instrument to assess leg strength, coordination and balance.^{89 90} A traffic cone is placed 3 m before a chair and participants are instructed to stand up from the chair, again without support of their arms, walk around the cone as fast as possible and take place on the chair again, while the time is recorded. The TUG Test is also performed three times, and the mean of the attempts is calculated. Handgrip strength is measured with the Jamar Hydraulic Hand Dynamometer (Jamar 5030J1, Patterson Medical, Warrenville, Canada). Participants are asked to clench the device with maximum force to perform an isometric contraction, first with the right hand and then with the left hand, while sitting on a chair. Participants are not allowed to rest their elbow on a table. Handgrip strength is tested three times with an interval of 30 s between each attempt, and the mean is calculated. The second handle position of the hand dynamometer is used because it has been shown to be the most accurate position.⁹¹

Cardiac structure, function and strain

Cardiac structure, volumes, systolic and diastolic function and global longitudinal strain are analysed with a resting transthoracic echocardiography at the baseline study visit and after 24 weeks. A Vivid E90 cardiovascular ultrasound system (GE Healthcare, Chicago, USA) is used. Imaging and analysis are performed by a blinded sonographer under supervision of a blinded cardiologist. Ventricular wall thickness and atrial and ventricular volumes are measured using two-dimensional echocardiography. Left ventricular ejection fraction as the main parameter of cardiac function is calculated from these measurements using the Simpson biplane method if image quality is sufficient, or is alternatively assessed by eyeballing. Ventricular mass is also calculated. Tricuspid annular plane systolic excursion is measured as a parameter of right ventricular function. Doppler imaging is used to assess diastolic function and blood flow velocity distal to the valves, from which pressure gradients are calculated.

Global longitudinal strain is evaluated as an early measure of impaired myocardial contractility, using cardiac performance analysis. Furthermore, troponin T and N-terminal pro-B-type natriuretic peptide as markers of myocardial injury and dysfunction are measured at baseline and after 12 and 24 weeks.

Quality of life

Participants are being requested to complete four questionnaires at baseline and after 24 weeks, to assess quality of life and level of fatigue. The Short Form-36 Questionnaire is used to measure health-related quality of life.⁹² Subjective fatigue, is assessed using the Dutch 'Checklist Individuele Spankrant' and the Dutch Multifactor Fatigue Scale.⁹³ Overall quality of life is measured with the EuroQol-5D-5L Questionnaire and Visual Analogue Scale.⁹⁴

Neurocognitive function

Neurocognitive performance of study participants is assessed by neuropsychology students at baseline and after 24 weeks, using a set of neuropsychological tests. Raw scores and norm scores, specific for age, sex and educational level, will be used for analysis.

At baseline, three tests are used to screen for signs of neurocognitive disorders and intellectual disability. The Cognitive Screening Test (CST) is a Dutch orientation questionnaire to screen for neurodegenerative disorders such as dementia.⁹⁵ The Clock Drawing Test (CDT) is a second CST for neurodegenerative disorders.⁹⁶ Participants are asked to draw a clock and set the time to 'a quarter to two'. The Nederlandse Leestest voor Volwassenen (NLV), the Dutch version of the National Adult Reading Test, provides an estimation of premorbid intelligence.⁹⁷ The participant has to read out 50 irregularly spelled words. Participants with signs of a neurodegenerative disorder based on the CST or the CDT or with an intellectual disability based on the NLV (estimated IQ<80) will be excluded from further cognitive analyses.

Three tests are performed to assess memory. The Digit Span Forward (Digit Span FW; subtest of the Wechsler Adult Intelligence Scale IV) measures memory span.⁹⁸ In this task, the participant is asked to repeat a series of numbers in the same order as the examiner did. The 15

Words Test (15WT; Dutch version of the Rey Auditory Verbal Learning Test) measures verbal memory, specifically immediate verbal memory (15WT Immediate Recall (IR)) and delayed verbal memory (15WT Delayed Recall (DR)).⁹⁹ In this task, 15 unrelated words are presented to the participant in 5 trials, who is asked to recall as many as possible after each trial (15WT IR). IR is the total score over five trials. After 20 min, participants are again asked to recall as many of the 15 words as possible (15WT DR). Word Fluency (subtest of the Groninger Intelligentie Test 2) is a verbal task measuring semantic memory.¹⁰⁰ Participants are asked to produce as many words within two semantic categories (animals and professions) within 1 min each.

Attention and mental speed are assessed using two tests. The Symbol Digit Modalities Test measures information processing speed.¹⁰¹ Participants are asked to combine as many symbols as possible with matching numbers within 90 s. The Trail Making Test part A (TMT-A) measures visuomotor and mental speed.¹⁰² In this paper and pencil task, participants are challenged to connect a series of randomly distributed numbers from 1 to 25 in an ascending order. The score is time in seconds to complete the task.

To assess executive functioning, three tests are performed. The Trail Making Test part B measures cognitive flexibility.¹⁰² This task is similar to the TMT-A, but numbers as well as letters have to be connected in an alternating ascending order (1-A-2-B- etc). Again, the score is time in seconds to complete the task. The Controlled Oral Word Association Test is used to measure executive control.¹⁰³ Participants are asked to produce as many words as possible that start with a specific letter (D-A-T) within 1 min. The three scores are added up. The Digit Span Backward (subtest of the Wechsler Adult Intelligence Test) measures working memory, which is considered an aspect of executive functioning.⁹⁸ The test is similar to the Digit Span FW, but this time, the participant is asked to repeat a series of numbers in the opposite order as the examiner did.

Adverse effects and safety

The occurrence of gastrointestinal side effects is examined using the Gastrointestinal Symptom Rating Scale Questionnaire, which is completed by the participant at baseline and after 24 weeks.¹⁰⁴ At all study visits, participants are being asked about adverse symptoms and new clinical events, particularly infections, hospitalisations, cardiovascular events and bone fractures. Plasma creatinine and hepatic transaminases are measured to screen for kidney or liver injury after treatment. Additionally, episodes of biopsy-proven rejection will be documented until the last visit of the last participant. Hypersensitivity reactions, cases of hypophosphatemia and other adverse events are registered systematically. To investigate the effect of ferric carboxymaltose on bone and mineral metabolism, blood levels of phosphate, calcium and parathyroid hormone are measured at all study visits. Phosphate and calcium

excretion are assessed using 24-hour urine. C-terminal and intact FGF23 levels, 25-hydroxycholecalciferol and 1.25-dihydroxycholecalciferol will be measured from stored blood samples after trial completion. Severe adverse events are reported to the medical ethical committee.

Exploratory outcomes

To investigate whether intravenous iron decreases the occurrence of restless leg syndrome, participants are asked whether in the past 2 weeks, they had experienced 'an often unpleasant or uncomfortable urge to move the legs that occurs during periods of inactivity, particularly in the evenings, and is transiently relieved by movement' at all study visits. Furthermore, to assess the potential effect of intravenous iron on kidney function, estimated glomerular filtration rate will be calculated using the 2021 CKD Epidemiology Collaboration (CKD-EPI) formula,¹⁰⁵ and 24-hour urine will be used to assess creatinine clearance and kidney damage markers including neutrophil gelatinase-associated lipocalin and kidney injury molecule-1.

At baseline and after 24 weeks, peripheral blood mononuclear cells (PBMCs) are isolated from whole blood. Stored PBMCs can be used to assess the effect of iron supplementation on lymphocytes. We will assess subset distribution of PBMCs, proliferation rate of in vitro stimulated T-lymphocytes and B-lymphocytes and plasma cell formation and cytokine expression of B-lymphocytes, using flow cytometry. Furthermore, B-lymphocyte immunoglobulin production is measured using ELISA. Blood samples are stored for the measurement of complement factors and cytokines as well.

Finally, participants are requested to bring a frozen faeces sample at baseline and after 24 weeks, which are stored for analysis. The effects of intravenous iron supplementation on gut microbiota will be assessed using 16S ribosomal RNA sequencing to identify different bacteria and liquid chromatography-mass spectrometry to analyse metabolomics.

Data analysis

Data analysis will be performed primarily according to the intention-to-treat principle for the allocated treatment and will include all participants who received at least one dose of study medication. An additional sensitivity analysis will be performed, in which only participants who received at least one treatment according to the allocated arm and who were still (patients in the placebo arm) or no longer (patients in the intervention arm) iron deficient at the last study visit will be included. Continuous data will be presented as mean with standard deviation (normally distributed data), median with interquartile range (data with a skewed distribution) or as number with percentages (categorical data). To evaluate changes in the continuous variables from baseline to week 6, 12, 18 and 24, paired t-tests or Wilcoxon signed-rank tests will be used. The

primary endpoint and secondary endpoints with data at baseline and the end-of-study visit will be analysed using mixed model analysis, thereby adjusting for baseline values. A *p* value of <0.05 will be considered significant. We do not expect to encounter a high number of missing data, but in the case of >10% incompleteness, missing values will be replaced by estimates. Statistical analyses will be performed with SPSS (IBM, Armonk, New York, United States of America, version 28.0) software.

Data management

Study data will be recorded digitally using the secured REDCap electronic data capture tool (REDCap, Nashville, USA)¹⁰⁶ hosted at the UMCG. Data and biological materials will be stored for 15 years. Data analysis will take place with validated and pseudoanonymised data. To protect participant privacy, public access to the dataset will not be provided. After the last visit of the last participant and before disclosure of treatment arm allocation, data will be extracted from REDCap and exported to SPSS for analysis. No interim analyses will be performed.

Ethics and dissemination

The study protocol has been approved by the local ethics committee (Medisch Ethische Toetsingscommissie UMCG, METc 2018/482, Protocol version: V.6.2, May 2022). Protocol modifications are reviewed by the ethics committee and are communicated to the full study team, current participants and trial registries. All study participants must provide written informed consent to the study doctor before enrolment. Study funders are not involved in the composition of the study design and data collection and will not be involved in data analysis or the decision to publish the results. Study results will be presented in publications in peer-reviewed scientific journals and at relevant international conferences. Authors will be selected according to eligibility guidelines and no professional writers will be involved.

Trial status

Recruitment started in October 2019 and is currently ongoing. Between March and June 2020, recruitment was temporarily halted because of the COVID-19 pandemic. Between March and May 2020, no in-hospital study visits were allowed. Given the uncertainty about the duration of the pandemic, it was decided that for patients who missed two or more study treatments, of which at least one because of the pandemic restrictions, participation would be terminated. In that case, the participant would not be included in the enrolment number and a new participant would be recruited instead. Participants who were excluded because of missed study drug administrations during the COVID-19 epidemic were invited for a rescreening under a new study number, providing they were still iron deficient. End-of-study visits were either postponed, with a maximum of 2 weeks, or were

performed at the participant's home if possible. This procedure has been approved by the medical ethical committee of the UMCG. We expect to include the last participant in early 2023 and to complete the trial in the second half of 2023.

Author affiliations

¹Department of Nephrology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands

²Department of Neuropsychology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands

³Department of Immunology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands

⁴Department of Nephrology, University Medical Centre Utrecht, Utrecht, The Netherlands

⁵Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

Twitter Martin H de Borst @mhdeborst

Contributors JSJV primarily wrote the study design and coordinated the trial. MFE and CAJMG contributed to the study design with expertise in iron metabolism. JMS cooperated in the setup of the design as an expert in cognitive assessment. J-SS and WHA contributed to the study design with expertise as a transplant immunology specialists. SJLB and SPB contributed to the study design with expertise in kidney transplantation research. PvdM supervised the writing of the design of the cardiometabolic assessments. ADvZ coordinated the local trial execution at the University Medical Centre Utrecht. MdB is the principal investigator of the study and supervised composition of the study design.

Funding This work was supported by the Dutch Kidney Foundation (grant no 170KG18) and by Vifor Fresenius Medical Care Pharma.

Competing interests JSJV has received consultancy fees from Vifor Pharma (to employer). MFE has declared receiving consultant fees from Vifor Pharma; serving on the Advisory Board for Cablon Medical; and receiving speakers bureaus from Vifor Pharma. CAJMG takes part in the advisory board of Vifor Pharma, GlaxoSmithKline and Pharmacosmos. PvdM received consultancy fees and/or grants from Novartis, Pharmacosmos, Vifor Pharma, AstraZeneca, Pfizer, Abbott, Pharma Nord, Novo Nordisk and Ionis. MdB has consultancy agreements with Amgen, Astellas, AstraZeneca, Bayer, Kyowa Kirin, Vifor Fresenius Medical Care Renal Pharma and Sanofi Genzyme and received grant support from Sanofi Genzyme and Vifor Pharma (all to employer).

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods and analysis section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Joanna SJ Vinke <http://orcid.org/0000-0002-5469-1156>

Michele F Eisenga <http://orcid.org/0000-0002-2484-6233>

Martin H de Borst <http://orcid.org/0000-0002-4127-8733>

REFERENCES

- 1 Riess KJ, Gourishankar S, Oreopoulos A, *et al*. Impaired arterial compliance and aerobic endurance in kidney transplant recipients. *Transplantation* 2006;82:920–3.
- 2 Stam SP, Eisenga MF, Gomes-Neto AW, *et al*. Muscle mass determined from urinary creatinine excretion rate, and muscle performance in renal transplant recipients. *J Cachexia Sarcopenia Muscle* 2019;10:621–9.

- 3 Zelle DM, Corpeleijn E, Stolk RP, *et al.* Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. *Clin J Am Soc Nephrol* 2011;6:898–905.
- 4 Chan W, Chin SH, Whittaker AC, *et al.* The associations of muscle strength, muscle mass, and adiposity with clinical outcomes and quality of life in prevalent kidney transplant recipients. *J Ren Nutr* 2019;29:536–47.
- 5 Eisenga MF, Minović I, Berger SP, *et al.* Iron deficiency, anemia, and mortality in renal transplant recipients. *Transpl Int* 2016;29:1176–83.
- 6 Lorenz M, Kletzmayer J, Perschl A, *et al.* Anemia and iron deficiencies among long-term renal transplant recipients. *J Am Soc Nephrol* 2002;13:794–7.
- 7 Molnar MZ, Czira M, Ambrus C, *et al.* Anemia is associated with mortality in kidney-transplanted patients -- a prospective cohort study. *Am J Transplant* 2007;7:818–24.
- 8 Molnar MZ, Mucsi I, Macdougall IC, *et al.* Prevalence and management of anaemia in renal transplant recipients: data from ten European centres. *Nephron Clin Pract* 2011;117:c127–34.
- 9 Ayerdem G, van Hassel G, Vinke JSJ, *et al.* Iron deficiency, with and without anaemia, across strata of kidney function in kidney transplant recipients. *Nephrol Dial Transplant* 2021;36:2342–4.
- 10 Camaschella C. Iron deficiency. *Blood* 2019;133:30–9.
- 11 Hoes MF, Grote Beverborg N, Kijlstra JD, *et al.* Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. *Eur J Heart Fail* 2018;20:910–9.
- 12 Dziegala M, Kobak KA, Kasztura M, *et al.* Iron depletion affects genes encoding mitochondrial electron transport chain and genes of non-oxidative metabolism, pyruvate kinase and lactate dehydrogenase, in primary human cardiac myocytes cultured upon mechanical stretch. *Cells* 2018;7:175.
- 13 Petrak J, Havlenova T, Krijt M, *et al.* Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. *Biochim Biophys Acta Gen Subj* 2019;1863:703–13.
- 14 Chung YJ, Luo A, Park KC, *et al.* Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity. *JCI Insight* 2019;4:e125618.
- 15 Barrientos T, Laothamatas I, Koves TR, *et al.* Metabolic catastrophe in mice lacking transferrin receptor in muscle. *EBioMedicine* 2015;2:1705–17.
- 16 Leermakers PA, Remels AHV, Zonneveld MI, *et al.* Iron deficiency-induced loss of skeletal muscle mitochondrial proteins and respiratory capacity; the role of mitophagy and secretion of mitochondria-containing vesicles. *FASEB J* 2020;34:6703–17.
- 17 Jankowska EA, Rozentryt P, Witkowska A, *et al.* Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. *J Card Fail* 2011;17:899–906.
- 18 Ebner N, Jankowska EA, Ponikowski P, *et al.* The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. results from the studies investigating co-morbidities aggravating heart failure. *Int J Cardiol* 2016;205:6–12.
- 19 Bekfani T, Pellicori P, Morris D, *et al.* Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. *Clin Res Cardiol* 2019;108:203–11.
- 20 Grote Beverborg N, van der Wal HH, Klip IJT, *et al.* Differences in clinical profile and outcomes of low iron storage vs defective iron utilization in patients with heart failure: results from the DEFINE-HF and BIOSTAT-CHF studies. *JAMA Cardiol* 2019;4:696–701.
- 21 Alcaide-Aldeano A, Garay A, Alcobero L, *et al.* Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. *J Clin Med* 2020;9:1199.
- 22 Kurz K, Lanser L, Seifert M, *et al.* Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. *ESC Heart Fail* 2020;7:1880–90.
- 23 Melenovsky V, Hlavata K, Sedivy P, *et al.* Skeletal muscle abnormalities and iron deficiency in chronic heart failure. *Circ Heart Failure* 2018;11.
- 24 Okonko DO, Grzeslo A, Witkowski T, *et al.* Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. *J Am Coll Cardiol* 2008;51:103–12.
- 25 Anker SD, Comin Colet J, Filippatos G, *et al.* Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;361:2436–48.
- 26 Ponikowski P, van Veldhuisen DJ, Comin-Colet J, *et al.* Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015;36:657–68.
- 27 van Veldhuisen DJ, Ponikowski P, van der Meer P, *et al.* Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. *Circulation* 2017;136:1374–83.
- 28 Martens P, Dupont M, Dauw J, *et al.* The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. *Eur Heart J* 2021;42:4905–14.
- 29 Del Canto I, Santas E, Cardells I, *et al.* Short-term changes in left and right ventricular cardiac magnetic resonance feature tracking strain following ferric carboxymaltose in patients with heart failure: a substudy of the myocardial-IRON trial. *J Am Heart Assoc* 2022;11:e022214.
- 30 Martens P, Dupont M, Dauw J, *et al.* The effect of intravenous ferric carboxymaltose on right ventricular function-insights from the IRON-CRT trial. *Eur J Heart Fail* 2022;24:1106–13.
- 31 Charles-Edwards G, Amaral N, Sleight A, *et al.* Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. *Circulation* 2019;139:2386–98.
- 32 Ponikowski P, Kirwan B-A, Anker SD, *et al.* Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet* 2020;396:1895–904.
- 33 Santer P, McGahey A, Frise MC, *et al.* Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. *BMJ Open Respir Res* 2020;7:e000577.
- 34 Motonishi S, Tanaka K, Ozawa T. Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients. *PLoS One* 2018;13:e0201662.
- 35 Guedes M, Muenz D, Zee J, *et al.* Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. *Nephrol Dial Transplant* 2021;36:1694–703.
- 36 Cho ME, Hansen JL, Peters CB, *et al.* An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic veterans with predialysis chronic kidney disease. *Kidney Int* 2019;96:750–60.
- 37 Guedes M, Muenz DG, Zee J, *et al.* Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia. *J Am Soc Nephrol* 2021;32:2020–30.
- 38 Mehta R, Cai X, Hodakowski A, *et al.* Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study. *Clin J Am Soc Nephrol* 2017;12:1795–803.
- 39 Mizuiri S, Nishizawa Y, Doi T, *et al.* Iron, coronary artery calcification, and mortality in patients undergoing hemodialysis. *Ren Fail* 2021;43:371–80.
- 40 Kuo K-L, Liu J-S, Lin M-H, *et al.* Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study. *Sci Rep* 2022;12:1269.
- 41 Bhandari S, Allgar V, Lamplugh A, *et al.* A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status. *BMC Nephrol* 2021;22:115.
- 42 Macdougall IC, White C, Anker SD, *et al.* Intravenous iron in patients undergoing maintenance hemodialysis. *N Engl J Med* 2019;380:447–58.
- 43 Joshee P, Wood AG, Wood ER, *et al.* Meta-analysis of cognitive functioning in patients following kidney transplantation. *Nephrol Dial Transplant* 2018;33:1268–77.
- 44 Ziengs AL, Buunk AM, van Sonderen L, *et al.* Long-term cognitive impairments in kidney transplant recipients: impact on participation and quality of life. *Nephrol Dial Transplant* 2023;38:491–8.
- 45 Hare D, Ayton S, Bush A, *et al.* A delicate balance: iron metabolism and diseases of the brain. *Front Aging Neurosci* 2013;5:34.
- 46 Blanton CA, Green MW, Kretsch MJ. Body iron is associated with cognitive executive planning function in college women. *Br J Nutr* 2013;109:906–13.
- 47 Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. *Am J Clin Nutr* 2007;85:778–87.
- 48 Dziembowska I, Kwapisz J, Izdebski P, *et al.* Mild iron deficiency may affect female endurance and behavior. *Physiol Behav* 2019;205:44–50.
- 49 Gong Z, Song W, Gu M, *et al.* Association between serum iron concentrations and cognitive impairment in older adults aged 60 years and older: a dose-response analysis of national health and nutrition examination survey. *PLoS One* 2021;16:e0255595.
- 50 Xu J, Sun W, Yang L. Association between iron metabolism and cognitive impairment in older non-alcoholic fatty liver disease

- individuals: a cross-sectional study in patients from a Chinese center. *Medicine (Baltimore)* 2019;98:e18189.
- 51 Jáuregui-Lobera I. Iron deficiency and cognitive functions. *Neuropsychiatr Dis Treat* 2014;10:2087–95.
 - 52 Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. *Lancet* 1996;348:992–6.
 - 53 Wenger MJ, Rhoten SE, Murray-Kolb LE, et al. Changes in iron status are related to changes in brain activity and behavior in Rwandan female university students: results from a randomized controlled efficacy trial involving iron-biofortified beans. *J Nutr* 2019;149:687–97.
 - 54 Schaefer B, Effenberger M, Zoller H. Iron metabolism in transplantation. *Transpl Int* 2014;27:1109–17.
 - 55 Jiang Y, Li C, Wu Q, et al. Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. *Nat Commun* 2019;10:2935.
 - 56 Resch T, Ashraf MI, Ritschi PV, et al. Disturbances in iron homeostasis result in accelerated rejection after experimental heart transplantation. *J Heart Lung Transplant* 2017;36:732–43.
 - 57 Vaugier C, Amano MT, Chemouny JM, et al. Serum iron protects from renal postischemic injury. *J Am Soc Nephrol* 2017;28:3605–15.
 - 58 Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. *J Bone Miner Res* 2013;28:1793–803.
 - 59 David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. *Kidney Int* 2016;89:135–46.
 - 60 Evenepoel P, Naesens M, Claes K, et al. Tertiary “hyperphosphatoninism” accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. *Am J Transplant* 2007;7:1193–200.
 - 61 Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary “hyper-phosphatoninism”? *Kidney Int* 2006;70:1486–94.
 - 62 Andrukhova O, Slavic S, Odörfer KI, et al. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. *J Bone Miner Res* 2015;30:1831–9.
 - 63 Yokomoto-Umakoshi M, Umakoshi H, Miyazawa T, et al. Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiometabolic disorders: a mendelian randomization study. *Bone* 2021;143.
 - 64 Desbiens L-C, Sidibé A, Ung R-V, et al. FGF23-klotho axis and fractures in patients without and with early CKD: a case-cohort analysis of cartagene. *J Clin Endocrinol Metab* 2022;107:e2502–12.
 - 65 Vervloet MG. Renal and extrarenal effects of fibroblast growth factor 23. *Nat Rev Nephrol* 2019;15:109–20.
 - 66 van der Wal HH, Grote Beverborg N, Ter Maaten JM, et al. Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. *Eur J Heart Fail* 2020;22:903–6.
 - 67 Eisenga MF, De Jong MA, Van der Meer P, et al. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: a cohort study. *PLoS Med* 2019;16:e1002818.
 - 68 Eisenga MF, van Londen M, Leaf DE, et al. C-Terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients. *J Am Soc Nephrol* 2017;28:3639–46.
 - 69 Baia LC, Humalda JK, Vervloet MG, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. *Clin J Am Soc Nephrol* 2013;8:1968–78.
 - 70 Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. *J Am Soc Nephrol* 2011;22:956–66.
 - 71 Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. *JCI Insight* 2018;3.
 - 72 Kortman GAM, Raffatelli M, Swinkels DW, et al. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. *FEMS Microbiol Rev* 2014;38:1202–34.
 - 73 La Carpi F, Wojczyk BS, Annavajhala MK, et al. Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron. *NPJ Biofilms Microbiomes* 2019;5:26.
 - 74 Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. *Gut* 2017;66:863–71.
 - 75 Lopez R, Micoulaud Franchi J-A, Chenini S, et al. Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder. *Sleep* 2019;42.
 - 76 Telarović S, Čondić L. Frequency of iron deficiency anemia in pregnant and non-pregnant women suffering from restless legs syndrome. *Hematology* 2019;24:263–7.
 - 77 Avni T, Reich S, Lev N, et al. Iron supplementation for restless legs syndrome—a systematic review and meta-analysis. *Eur J Intern Med* 2019;63:34–41.
 - 78 Yang X, Yang B, Ming M, et al. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies. *Sleep Med* 2019;61:110–7.
 - 79 Macher S, Herster C, Holter M, et al. The effect of parenteral or oral iron supplementation on fatigue, sleep, quality of life and restless legs syndrome in iron-deficient blood donors: a secondary analysis of the ironwoman RCT. *Nutrients* 2020;12:1313.
 - 80 Molnar MZ, Novak M, Szeifert L, et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. *J Psychosom Res* 2007;63:591–7.
 - 81 Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One* 2015;10:e0117383.
 - 82 Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. *Int J Cardiol* 2013;168:349–42.
 - 83 Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. *Nephrol Dial Transplant* 2014;29:2075–84.
 - 84 Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. *J Am Coll Cardiol* 2007;50:1657–65.
 - 85 Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. *JAMA* 2017;317:1958–66.
 - 86 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;166:111–7.
 - 87 Solway S, Brooks D, Lacasse Y, et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest* 2001;119:256–70.
 - 88 Welle S, Thornton C, Totterman S, et al. Utility of creatinine excretion in body-composition studies of healthy men and women older than 60 Y. *Am J Clin Nutr* 1996;63:151–6.
 - 89 Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc* 1991;39:142–8.
 - 90 Kwan MM-S, Lin S-I, Chen C-H, et al. Sensorimotor function, balance abilities and pain influence timed up and go performance in older community-living people. *Aging Clin Exp Res* 2011;23:196–201.
 - 91 Trampisch US, Franke J, Jedamzik N, et al. Optimal jamar dynamometer handle position to assess maximal isometric hand grip strength in epidemiological studies. *J Hand Surg Am* 2012;37:2368–73.
 - 92 Ware JE, Sherbourne CD. The mos 36-item short-form health survey (SF-36). I. conceptual framework and item selection. *Med Care* 1992;30:473–83.
 - 93 Visser-Keizer AC, Hogenkamp A, Westerhof-Evers HJ, et al. Dutch multifactor fatigue scale: a new scale to measure the different aspects of fatigue after acquired brain injury. *Arch Phys Med Rehabil* 2015;96:1056–63.
 - 94 Group E. EuroQol -- a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
 - 95 Graaf Ad. *Cognitieve screening test handleiding*. 1991.
 - 96 Shulman KI, Shedletsky R, Silver IL. The challenge of time: clock-drawing and cognitive function in the elderly. *Int J Geriatr Psychiatry* 1986;1:135–40.
 - 97 Schmand B, Bakker D, Saan R, et al. De Nederlandse Leestest voor Volwassenen: een maat voor het premorbid intelligentieniveau [The Dutch Reading Test for Adults: a measure of premorbid intelligence level]. *Tijdschr Gerontol Geriatr* 1991;22:15–9.
 - 98 Stinissen J, Willems PJ, Coetsier P, et al. *Handleiding bij de nederlandse bewerking van de wechsler adult intelligence scale (W. A. I. S.) [manual of the dutch edition of the wechsler adult intelligence scale]*. Lisse, Switzerland: Swets & Zeitlinger, 1970.
 - 99 Saan R. *De 15-woorden tests A en B. (een voorlopige handleiding)*. 1986.
 - 100 Luteijn F. *GIT2: groningen intelligentie test 2*. 2004.
 - 101 Smith A. *Symbol digits modalities test*. Los Angeles: Western Psychological Services, 1968.
 - 102 Reitan R, Wolfson D. *The halstead-reitan neuropsychological test battery: theory and clinical interpretation*. Neuropsychol Press, 1985.

- 103 Schmand B, Groenink SC, den Dungen M. Letterfluency: psychometrische eigenschappen en nederlandse normen. *GEEG* 2008;39:64–74.
- 104 Svedlund J, Sjödin I, Dotevall G. GSRS -- a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. *Dig Dis Sci* 1988;33:129–34.
- 105 Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–12.
- 106 Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (redcap) — a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.